Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Wang X, Barrera C, Bera K, Viswanathan VS, Azarianpour-Esfahani S, Koyuncu C, et al. Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Sci Adv. 2022;8(22):eabn3966.

Kato T, Asakura T, Edwards CE, Dang H, Mikami Y, Okuda K, et al. Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. Am J Respir Crit Care Med. 2022;206(11):1336-1352.

Tow CY, Castrodad-Rodríguez CA, Panarelli N, Massoumi H. Finding Nivo: A Case Report of 2 Forms of Nivolumab-Induced Liver Injury in an Allograft Liver in the Immediate Post-Transplant Period. Transplant Proc. 2022;54(10):2794-2796.

Guerrero-Preston R, Rivera-Amill V, Caraballo K, Rodriguez-Torres S, Purcell-Wiltz A, García AA, et al. Precision health diagnostic and surveillance network uses S gene target failure (SGTF) combined with sequencing technologies to track emerging SARS-CoV-2 variants. Immun Inflamm Dis. 2022;10(6):e634.

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022;376(6596):eabe1505.

Boyraz B, Tajiri R, Alwaqfi RR, Paula AD, Ye Q, G Nielsen P, et al. Vulvar angiomyofibroblastoma is molecularly defined by recurrent MTG1-CYP2E1 fusions. Histopathology. 2022;81(6):841-846.

Magro C, Shapiro L. Exploring the pathophysiologic basis of constrictive pericarditis of Kohlmeier Degos disease: A case series and review of the literature. Ann Diagn Pathol. 2022;59:151943.

Liu C, Zhou N, Levitan D, Guzman JC, Fehniger J. Cutaneous metastasis of PD-L1 positive cervical carcinoma. Gynecol Oncol Rep. 2022;41:101003.

Vougiouklakis T, Zhu K, Vasudevaraja V, Serrano J, Shen G, Linn RL, et al. Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements. Clin Cancer Res. 2022;28(8):1724-1733.

Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat Commun. 2022;13(1):2559.